A study has revealed that downregulation of ABCC4 increases sensitivity to neoadjuvant chemoradiotherapy and longer disease-free survival in rectal cancer patients has been demonstrated [15, 16], which suggested that ABCC4 might be a possible predictive biomarker for the efficacy of chemotherapy in rectal carcinoma. The gene discussed is ABCC4; the disease is rectal carcinoma.